Search Results - "Kantoff, P. W."

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A by Sun, T, Wang, X, He, H H, Sweeney, C J, Liu, S X, Brown, M, Balk, S, Lee, G-SM, Kantoff, P W

“…Hormone-sensitive prostate cancer typically progresses to castration resistant prostate cancer (CRPC) after the androgen deprivation therapy. We investigated…”
Get full text

TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort by DEMICHELIS, F, FALL, K, ADAMI, H.-O, MUCCI, L. A, KANTOFF, P. W, ANDERSSON, S.-O, CHINNAIYAN, A. M, JOHANSSON, J.-E, RUBIN, M. A, PERNER, S, ANDREN, O, SCHMIDT, F, SETLUR, S. R, HOSHIDA, Y, MOSQUERA, J.-M, PAWITAN, Y, LEE, C

“…The identification of the TMPRSS2:ERG fusion in prostate cancer suggests that distinct molecular subtypes may define risk for disease progression. In surgical…”
Get full text

Phase II study of sunitinib in men with advanced prostate cancer by Dror Michaelson, M., Regan, M.M., Oh, W.K., Kaufman, D.S., Olivier, K., Michaelson, S.Z., Spicer, B., Gurski, C., Kantoff, P.W., Smith, M.R.

“…This study explored the efficacy and tolerability of sunitinib, an inhibitor of tyrosine kinase receptors, in men with castration-resistant prostate cancer…”
Get full text

Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer by Michaelson, M.D., Bellmunt, J., Hudes, G.R., Goel, S., Lee, R.J., Kantoff, P.W., Stein, C.A., Lardelli, P., Pardos, I., Kahatt, C., Nieto, A., Cullell-Young, M., Lewis, N.L., Smith, M.R.

“…This multicenter phase II trial evaluated the efficacy and safety of trabectedin in metastatic castration-resistant prostate cancer (CRPC). Two schedules were…”
Get full text

Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study by KANTOFF, P. W, HALABI, S, CONAWAY, M, PICUS, J, KIRSHNER, J, HARS, V, TRUMP, D, WINER, E. P, VOGELZANG, N. J

“…Approximately 40,000 men die each year of hormone-refractory prostate cancer (HRPC). The results of treatment with chemotherapy have been disappointing to…”
Get full text

Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy by Talcott, James A., Rieker, Patricia, Propert, Kathleen J., Clark, Jack A., Kantoff, Philip W., Wishnow, Kenneth I., Loughlin, Kevin R., Richie, Jerome P.

“…Background: The age-adjusted rate of radical prostatectomy, the most common treatment of early (nonmetastatic) prostate cancer, increased almost sixfold…”
Get full text

Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men by Krithivas, K, Yurgalevitch, SM, Mohr, BA, Wilcox, CJ, Batter, SJ, Brown, M, Longcope, C, McKinlay, JB, Kantoff, PW

“…In men over 30 years old, serum levels of testosterone (T) decrease with age. A shorter polymorphic CAG repeat length in exon 1 of the androgen receptor (AR)…”
Get full text

Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study by Talcott, J A, Rieker, P, Clark, J A, Propert, K J, Weeks, J C, Beard, C J, Wishnow, K I, Kaplan, I, Loughlin, K R, Richie, J P, Kantoff, P W

“…To assess complications of therapy for early (nonmetastatic) prostate cancer. A prospective study of a cohort of 279 men who sought treatment advice and…”
Get more information

A prognostic index model for predicting overall survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone acetate after docetaxel by Chi, K.N., Kheoh, T., Ryan, C.J., Molina, A., Bellmunt, J., Vogelzang, N.J., Rathkopf, D.E., Fizazi, K., Kantoff, P.W., Li, J., Azad, A.A., Eigl, B.J., Heng, D.Y.C., Joshua, A.M., de Bono, J.S., Scher, H.I.

“…Few prognostic models for overall survival (OS) are available for patients with metastatic castration-resistant prostate cancer (mCRPC) treated with recently…”
Get full text

Complications after treatment with external-beam irradiation in early-stage prostate cancer patients: a prospective multiinstitutional outcomes study by Beard, C J, Propert, K J, Rieker, P P, Clark, J A, Kaplan, I, Kantoff, P W, Talcott, J A

“…To use data from a prospective quality-of-life study to assess differences in disease-specific and general health-related quality-of-life changes after…”
Get more information

Plasma levels of vascular endothelial growth factor are increased in patients with metastatic prostate cancer by Duque, Jose Luis F, Loughlin, Kevin R, Adam, Rosalyn M, Kantoff, Philip W, Zurakowski, David, Freeman, Michael R

“…Objectives. Vascular endothelial growth factor (VEGF) is a cytokine that plays an important role in tumor angiogenesis. VEGF is overexpressed in many human…”
Get full text

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors by Nelson, Joel B, Chen, Roland N, Bishoff, Jay T, Oh, William K, Kantoff, Philip W, Donehower, Ross C, Kavoussi, Louis R

“…Objectives. To assess retrospectively whether laparoscopic retroperitoneal lymph node dissection (RPLND) in patients with clinical Stage I nonseminomatous germ…”
Get full text

Role of diet in prostate cancer: the epigenetic link by Labbé, D P, Zadra, G, Ebot, E M, Mucci, L A, Kantoff, P W, Loda, M, Brown, M

“…Diet is hypothesized to be a critical environmentally related risk factor for prostate cancer (PCa) development, and specific diets and dietary components can…”
Get full text

Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate by Tay, M.-H., Kaufman, D. S., Regan, M. M., Leibowitz, S. B., George, D. J, Febbo, P. G., Manola, J., Smith, M. R., Kaplan, I. D., Kantoff, P. W., Oh, W. K.

“…Background: Medical or surgical castration is effective in advanced prostate cancer but with profound side-effects, particularly on sexual function. Effective,…”
Get full text

Detection of circulating tumor cells in men with localized prostate cancer by Seiden, M V, Kantoff, P W, Krithivas, K, Propert, K, Bryant, M, Haltom, E, Gaynes, L, Kaplan, I, Bubley, G, DeWolf, W

“…Using prostate-specific antigen (PSA) mRNA as a marker for prostatic epithelial cells, we have developed a sensitive technique that involves reverse…”
Get more information

Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC) by tripathi, A., Supko, J.G., Gray, K.P., Melnick, Z., Taplin, M.-E., Choudhury, A.D., Pomerantz, M., Bellmunt, J., Yu, C., Sun, Z., Srinivas, S., Kantoff, P.W., Sweeney, C., Harshman, L.C.

Get full text

The V89L polymorphism in the 5α-reductase type 2 gene and risk of prostate cancer by FEBBO, P. G, KANTOFF, P. W, PLATZ, E. A, CASEY, D, BATTER, S, GIOVANNUCCI, E, HENNEKENS, C. H, STAMPFER, M. J

“…5 alpha -Reductase type 2, the predominant prostatic isozyme of this protein, converts testosterone to dihydrotestosterone. It has been hypothesized that…”
Get full text

The CAG repeat within the androgen receptor gene and benign prostatic hyperplasia by Giovannucci, Edward, Platz, Elizabeth A, Stampfer, Meir J, Chan, Andrew, Krithivas, Krishna, Kawachi, Ichiro, Willett, Walter C, Kantoff, Philip W

“…Objectives. Shorter CAG repeat lengths in exon 1 of the androgen receptor (AR) gene are associated with a stronger transcriptional activity of the AR and with…”
Get full text

Effect of internal viral sequences on the utility of retroviral vectors by Armentano, D, Yu, S F, Kantoff, P W, von Ruden, T, Anderson, W F, Gilboa, E

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

The impact of comorbidity and PSA doubling time on the risk of death in men experiencing PSA failure following radiation therapy with or with androgen deprivation therapy for unfavorable-risk prostate cancer by Patel, S A, Chen, M-H, Loffredo, M, Renshaw, A, Kantoff, P W, D'Amico, A V

“…Background: The optimal management of men with PSA failure following initial prostate cancer (PC) therapy stratified by comorbidity is unknown. We investigated…”
Get full text